These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 29329113)

  • 21. HIV vaccine: hopes and hurdles.
    Chhatbar C; Mishra R; Kumar A; Singh SK
    Drug Discov Today; 2011 Nov; 16(21-22):948-56. PubMed ID: 21889604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
    Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
    J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Immune Interventions for an HIV-1 Cure.
    Perreau M; Banga R; Pantaleo G
    Trends Mol Med; 2017 Oct; 23(10):945-961. PubMed ID: 28890135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine and immunotherapeutic interventions.
    Pantaleo G; Lévy Y
    Curr Opin HIV AIDS; 2013 May; 8(3):236-42. PubMed ID: 23478912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New concepts in HIV-1 vaccine development.
    Stephenson KE; D'Couto HT; Barouch DH
    Curr Opin Immunol; 2016 Aug; 41():39-46. PubMed ID: 27268856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toward an antibody-based HIV-1 vaccine.
    Hoxie JA
    Annu Rev Med; 2010; 61():135-52. PubMed ID: 19824826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV Vaccination: A Roadmap among Advancements and Concerns.
    Trovato M; D'Apice L; Prisco A; De Berardinis P
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29671786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination.
    Martinez DR; Permar SR; Fouda GG
    Clin Vaccine Immunol; 2016 Feb; 23(2):84-94. PubMed ID: 26656117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent strategies targeting HIV glycans in vaccine design.
    Horiya S; MacPherson IS; Krauss IJ
    Nat Chem Biol; 2014 Dec; 10(12):990-9. PubMed ID: 25393493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Requirements for the Induction of Broadly Neutralizing Antibodies against HIV-1 by Vaccination].
    Vzorov AN; Uryvaev LV
    Mol Biol (Mosk); 2017; 51(6):945-957. PubMed ID: 29271959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
    Ahmed Y; Tian M; Gao Y
    AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 34. Advances in HIV-1 Vaccine Development.
    Gao Y; McKay PF; Mann JFS
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29614779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation.
    Yin J; Dai A; Lecureux J; Arango T; Kutzler MA; Yan J; Lewis MG; Khan A; Sardesai NY; Montefiore D; Ruprecht R; Weiner DB; Boyer JD
    Vaccine; 2011 Sep; 29(39):6763-70. PubMed ID: 21195801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.
    Voss JE; Andrabi R; McCoy LE; de Val N; Fuller RP; Messmer T; Su CY; Sok D; Khan SN; Garces F; Pritchard LK; Wyatt RT; Ward AB; Crispin M; Wilson IA; Burton DR
    Cell Rep; 2017 Oct; 21(1):222-235. PubMed ID: 28978475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic vaccination for HIV: hopes and challenges.
    Stephenson KE
    Curr Opin HIV AIDS; 2018 Sep; 13(5):408-415. PubMed ID: 29957615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV Vaccines: One Step Closer.
    Low MSY; Tarlinton D
    Trends Mol Med; 2017 Jan; 23(1):1-3. PubMed ID: 27889424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.